Lexeo Therapeutics, Inc. LXEO
3.23 USD 0.00 (+0.00%)
At closeNov 5, 2026, 8:42 AM EST
3.31 +0.08 +2.48%
Pre-market · Nov 5, 8:42 AM ET
Day range unavailable
2.55 52-week range 10.99
- YTD
- -67.47%
- 1 year
- -60.61%
Financial health
Altman Z-Score
5.50 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -5.3×
FY 2020 5y median -5.0× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 2.2×
FY 2020 5y median 1.8× FY 2025
P/FCF -5.4×
FY 2020 5y median -5.4× FY 2025
EV/EBITDA -4.9×
FY 2020 5y median -3.3× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -18.6%
FY 2020 5y median -18.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -40.5%
FY 2020 5y median -40.5% FY 2025
ROIC -42.9%
FY 2020 5y median -54.7% FY 2025
ROA -37.2%
FY 2020 5y median -47.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -3.3%
FY 2020 FY 2025
EPS (diluted) 39.8%
FY 2020 FY 2025
Free Cash Flow -21.2%
FY 2020 FY 2025
Financial Health
Current Ratio 11.2×
FY 2020 5y median 7.2× FY 2025
Quick Ratio 11.2×
FY 2020 5y median 7.2× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 0.6×
FY 2020 5y median 1.1× FY 2025
Interest Coverage -530×
FY 2020 5y median -530× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31